---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007193"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-09-16T20:05:25+00:00"
generated_at: "2026-09-16T20:06:05.789108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma majority owner approves reverse split up to 1-for-20

## Summary
- Dr. Steve N. Slilaty, CEO, holding ~97% voting power, approved reverse split via written consent on Sept 15, 2026.
- Board authorized to effect split at ratio up to 1-for-20, with exact whole-number ratio at board's discretion.
- Consent effective 20 days after definitive information statement mailed to stockholders.
- Split applies to common stock (SBFM); warrants (SBFMW) also listed on Nasdaq.
- No timeline for board decision; action allows flexibility to meet listing requirements.

## SEC filing metadata
- accession: 0001683168-26-007193
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-09-16T20:05:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/0001683168-26-007193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007193
- JSON: https://secwatch.observer/filing/0001683168-26-007193.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.